What's Happening?
Eli Lilly's new oral GLP-1 agonist, Foundayo, has experienced a slower market uptake compared to Novo Nordisk's Wegovy, according to initial data from IQVIA. Analysts at Jefferies reported that Foundayo prescriptions were 1,390 in its first week and 3,707
in the second week. In contrast, Wegovy, which launched earlier, saw over 3,000 prescriptions in its first few days and 18,410 in its second week. The demand for Wegovy was likely boosted by its status as the first oral alternative to injectable GLP-1 drugs for weight loss. Despite the slower start, Lilly emphasizes Foundayo's convenience, as it can be taken at any time without food or water restrictions, unlike Wegovy, which must be taken on an empty stomach. Novo Nordisk, however, leverages its brand recognition and claims superior efficacy for Wegovy.
Why It's Important?
The competition between Eli Lilly and Novo Nordisk in the weight-loss drug market is significant due to the growing demand for effective obesity treatments. The slower uptake of Foundayo could impact Lilly's market share and financial performance, especially as Novo Nordisk capitalizes on its first-mover advantage. The outcome of this competition could influence future drug development strategies and marketing approaches in the pharmaceutical industry. Investors and stakeholders are closely monitoring the companies' upcoming financial results for further insights into the market dynamics and the potential long-term success of these oral therapies.
What's Next?
Both Eli Lilly and Novo Nordisk are expected to release their first-quarter financial results soon, which will provide more detailed insights into the performance of their oral weight-loss drugs. Lilly's results are due on April 30, while Novo Nordisk will report on May 6. These updates will be crucial for assessing the market reception of Foundayo and Wegovy, as well as the impact on their injectable counterparts. The pharmaceutical industry will be watching closely to see how these developments affect the competitive landscape and future sales projections.
